Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review explores the complex factors involved in alopecia areata, such as immune and genetic influences, and discusses advances in diagnostic and therapeutic approaches, while reporting no new clinical results.

This manuscript reviews the latest understanding of alopecia areata's pathogenesis, highlighting the roles of genetic, immunological, and environmental factors, with a focus on immune responses involving IFN-γ and cytotoxic CD8+ T-cells as key contributors to hair follicle inflammation and function disruption without follicle destruction.

This review reports that Dang Gui (Radix Angelica sinensis) possesses bidirectional immunoregulatory effects, enhancing immune cell proliferation and function, and may benefit immune-related diseases such as cancer and anemia. It also evaluates regulatory and safety aspects, aiming to guide future research and clinical use.

This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.

This study found that expanding hair follicle keratinocytes with a fibroblast feeder followed by short-term coculture with dermal papilla cells could restore their ability to form new hair follicles.

In this study, ritlecitinib, an oral medication approved for adolescents and adults, significantly reduced scalp hair loss and promoted eyebrow and eyelash regrowth in severe alopecia areata patients, with benefits sustained over 48 weeks and generally well-tolerated minor side effects.

This review discusses the promising role of JAK inhibitors in managing alopecia areata, reporting significant hair regrowth and acceptable safety profiles but noting the need for further research on dosing and long-term safety.

This study evaluates the efficacy and safety of a higher dose (100-mg) of ritlecitinib for treating severe alopecia areata, comparing it to external and synthetic placebo control groups.

This review discusses the progress and challenges in delivering CRISPR/Cas9 systems for in vivo genome editing, highlighting current methods and opportunities for future therapeutic applications.

In this study, researchers found that gentamicin-loaded exosomes derived from a bovine leukocyte spleen extract significantly enhanced antimicrobial activity and tissue regeneration in infected diabetic wounds, showing potential as an effective therapeutic strategy for diabetic foot ulcers by improving infection control and promoting healing.

In this case report, a 55-year-old woman developed alopecia areata approximately one year into her treatment with upadacitinib for atopic dermatitis, raising questions about a potential drug-induced link that has not been reported before.

This study describes a new treatment algorithm for alopecia areata that includes both disease severity and quality-of-life considerations, highlighting recent therapeutic advances and the need for future validation and access equity.

In this case report, a 30-year-old male with alopecia universalis and autoimmune conditions experienced treatment failure with JAK inhibitors, including ritlecitinib, and developed severe musculoskeletal pain, indicating a potential novel adverse effect that warrants further pharmacovigilance.

This review discusses the application and potential of baricitinib, a JAK1/2 inhibitor, for treating dermatological diseases like alopecia areata and reports no new clinical results.

This study found that using 3D dermal papilla spheroid models enhances extracellular matrix production and hair follicle marker expression, providing insights into hair follicle biology and potential for drug screening.

This study observed that dupilumab led to significant hair regrowth and was well-tolerated in children with both alopecia areata and atopic dermatitis, showing promise as a safe treatment option for pediatric patients with associated atopy.

This review examines various pharmacological options for managing alopecia areata, highlighting the effectiveness of corticosteroids for mild to moderate cases and promising results from JAK inhibitors like baricitinib for more severe forms, with additional benefits from minoxidil and potential from other treatments.

This mini-review discusses the role of androgens, specifically testosterone and dihydrotestosterone, in the pathogenesis of autoimmune liver diseases and reports no new results.

This study found that finasteride treatment in male rats altered steroid hormone homeostasis and caused kidney damage, suggesting potential risks for patients with renal dysfunction on androgen or antiandrogen therapy.

In this study, researchers observed that individuals with alopecia areata exhibited significant changes in scalp microbiota diversity and composition, which were linked to disease severity and inflammation markers, though it remains unclear if these microbial shifts are a cause or a result of hair loss.

This study compared JAK inhibitors for moderate-to-severe alopecia areata and found brepocitinib 30mg and deuruxolitinib 12mg to be most effective, though deuruxolitinib may cause more adverse events. Further research is needed for long-term efficacy and safety.

This study highlights how combining genetic and environmental risk assessments could advance early screening and personalized prevention for vitiligo, given its genetic complexity and environmental interactions.

This article reviews treatment options for Alopecia Areata, concluding that topical corticosteroids are effective for mild cases, while systemic therapies are advised for moderate to severe cases.

This review highlights the various causes and treatment options for alopecia, noting that while non-scarring types often see successful hair regrowth, scarring forms require early intervention to manage inflammatory destruction of hair follicles.

This study reviewed recent theories on alopecia areata's pathogenesis, highlighting its autoimmune nature due to immune privilege disruption in hair follicles, and noted current treatments have limited efficacy with high relapse rates, underscoring the need for further research into its mechanisms for better therapies.

This review provides an overview of recent tissue engineering and regenerative medicine developments in Asia, highlighting significant advances, representative research achievements, and discussing future directions, without presenting new research results.

This review discusses current experimental approaches for regenerating human hair follicles using tissue engineering and isolated cells, but reports no successful strategies with adult cells yet found.

This review discusses the relationship between psoriasis and autoimmunity, focusing on autoimmune co-morbidities, but reports no new research findings.

This review summarizes recent findings on FOXN1's essential role in thymus and skin biology and discusses emerging therapeutic approaches for immune disorders with athymia, but reports no new clinical results.

This review highlights similarities in the development of thymus and skin epidermis, reporting no new results; the authors emphasize shared molecular mechanisms despite different embryonic origins.